NDAMDA: Network distance analysis for MiRNA‐disease association prediction

In recent years, microRNAs (miRNAs) are attracting an increasing amount of researchers’ attention, as accumulating studies show that miRNAs play important roles in various basic biological processes and that dysregulation of miRNAs is connected with diverse human diseases, particularly cancers. However, the experimental methods to identify associations between miRNAs and diseases remain costly and laborious. In this study, we developed a computational method named Network Distance Analysis for MiRNA‐Disease Association prediction (NDAMDA) which could effectively predict potential miRNA‐disease associations. The highlight of this method was the use of not only the direct network distance between 2 miRNAs (diseases) but also their respective mean network distances to all other miRNAs (diseases) in the network. The model's reliable performance was certified by the AUC of 0.8920 in global leave‐one‐out cross‐validation (LOOCV), 0.8062 in local LOOCV and the average AUCs of 0.8935 ± 0.0009 in fivefold cross‐validation. Moreover, we applied NDAMDA to 3 different case studies to predict potential miRNAs related to breast neoplasms, lymphoma, oesophageal neoplasms, prostate neoplasms and hepatocellular carcinoma. Results showed that 86%, 72%, 86%, 86% and 84% of the top 50 predicted miRNAs were supported by experimental association evidence. Therefore, NDAMDA is a reliable method for predicting disease‐related miRNAs.

[1]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[2]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[3]  K. Lindblad-Toh,et al.  The dog as a cancer model , 2006, Nature Biotechnology.

[4]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[5]  Xia Li,et al.  Prediction of potential disease-associated microRNAs based on random walk , 2015, Bioinform..

[6]  Jia Song,et al.  [Expressions of miR-21, miR-155 and miR-210 in plasma of patients with lymphoma and its clinical significance]. , 2012, Zhongguo shi yan xue ye xue za zhi.

[7]  T. Shackelford,et al.  The Oxford handbook of comparative evolutionary psychology , 2012 .

[8]  A. Pasquinelli,et al.  Control of developmental timing by micrornas and their targets. , 2002, Annual review of cell and developmental biology.

[9]  C. Pasquier,et al.  Prediction of miRNA-disease associations with a vector space model , 2016, Scientific Reports.

[10]  L. Lefebvre,et al.  Brains, Lifestyles and Cognition: Are There General Trends? , 2008, Brain, Behavior and Evolution.

[11]  T. Mallory,et al.  Malignant Lymphoma: A Clinico-Pathologic Survey of 618 Cases. , 1942, The American journal of pathology.

[12]  Xia Li,et al.  Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes , 2013, BMC Systems Biology.

[13]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[14]  Yun Xiao,et al.  Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[15]  C E Lipscomb,et al.  Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.

[16]  Qionghai Dai,et al.  RBMMMDA: predicting multiple types of disease-microRNA associations , 2015, Scientific Reports.

[17]  Yang Li,et al.  HMDD v2.0: a database for experimentally supported human microRNA and disease associations , 2013, Nucleic Acids Res..

[18]  Pio Zeppa,et al.  Non-Hodgkin Lymphoma. , 2020, Monographs in clinical cytology.

[19]  Z. Tian,et al.  Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells , 2011, Virology Journal.

[20]  Yu Sun,et al.  Serum MicroRNA-155 as a Potential Biomarker to Track Disease in Breast Cancer , 2012, PloS one.

[21]  E. R. L. Count.  LYMPHOMA, A BENIGN TUMOR REPRESENTING A LYMPH GLAND IN STRUCTURE , 1899 .

[22]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[23]  E. R. Le Count.  LYMPHOMA, A BENIGN TUMOR REPRESENTING A LYMPH GLAND IN STRUCTURE , 1899, The Journal of experimental medicine.

[24]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[25]  Recinda L. Sherman,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival , 2017, Journal of the National Cancer Institute.

[26]  Yadong Wang,et al.  Prioritization of disease microRNAs through a human phenome-microRNAome network , 2010, BMC Systems Biology.

[27]  Thomas Tuschl,et al.  MicroRNAs in human cancer. , 2013, Advances in experimental medicine and biology.

[28]  Qionghai Dai,et al.  WBSMDA: Within and Between Score for MiRNA-Disease Association prediction , 2016, Scientific Reports.

[29]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[30]  Xing Chen,et al.  HGIMDA: Heterogeneous graph inference for miRNA-disease association prediction , 2016, Oncotarget.

[31]  Xing Chen,et al.  Semi-supervised learning for potential human microRNA-disease associations inference , 2014, Scientific Reports.

[32]  Yadong Wang,et al.  miR2Disease: a manually curated database for microRNA deregulation in human disease , 2008, Nucleic Acids Res..

[33]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[34]  V. Ambros.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[35]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[36]  Stefanie Dimmeler,et al.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis. , 2008, Cardiovascular research.

[37]  Changning Liu,et al.  dbDEMC: a database of differentially expressed miRNAs in human cancers , 2010, BMC Genomics.

[38]  E. Wang,et al.  Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. , 2014, Seminars in cancer biology.

[39]  Masayuki Watanabe,et al.  Serum microRNA‐21 is a novel biomarker in patients with esophageal squamous cell carcinoma , 2012, Journal of surgical oncology.

[40]  Peter S Linsley,et al.  MicroRNAs and Cell Cycle Regulation , 2007, Cell cycle.

[41]  D. Iliopoulos,et al.  E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. , 2008, Cancer cell.

[42]  Weiying Zhou,et al.  UC Office of the President Recent Work Title De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer , 2012 .

[43]  Xing Chen,et al.  RWRMDA: predicting novel human microRNA-disease associations. , 2012, Molecular bioSystems.

[44]  Xing Chen,et al.  MCMDA: Matrix completion for MiRNA-disease association prediction , 2017, Oncotarget.

[45]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[46]  S. Suter,et al.  Identification of altered MicroRNA expression in canine lymphoid cell lines and cases of B‐ and T‐Cell lymphomas , 2011, Genes, chromosomes & cancer.

[47]  Edwin Wang,et al.  Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression. , 2009, Molecular bioSystems.

[48]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[49]  Jinfeng Zou,et al.  Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. , 2016, JAMA oncology.

[50]  Jan Gorodkin,et al.  Protein-driven inference of miRNA–disease associations , 2013, Bioinform..

[51]  P. Yu,et al.  Serum miR-21 expression in human esophageal squamous cell carcinomas. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[52]  S. Zhang,et al.  Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[53]  P. Sharp,et al.  MicroRNA functions in stress responses. , 2010, Molecular cell.

[54]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[55]  H. Baba,et al.  Clinical impact of serum exosomal microRNA‐21 as a clinical biomarker in human esophageal squamous cell carcinoma , 2013, Cancer.

[56]  Dong Wang,et al.  Inferring the human microRNA functional similarity and functional network based on microRNA-associated diseases , 2010, Bioinform..